Prothena Biosciences Ltd.
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1 Study of PRX019 in Healthy Adult Volunteers
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06699680
- Locations
- 🇺🇸
Local Institution, Los Alamitos, California, United States
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 208
- Registration Number
- NCT04973137
- Locations
- 🇺🇸
Yale Cancer Center, North Haven, Connecticut, United States
🇺🇸Smilow Cancer Hospital Care Center at Trumbull, Trumbull, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
Study in Subjects With Light Chain (AL) Amyloidosis
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT03154047
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Mayo Clinic Hospital - Florida, Jacksonville, Florida, United States
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT02632786
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Stanford Cancer Institute (SCI), Stanford, California, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Prothena Biosciences Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT02613182
- Locations
- 🇺🇸
Stanford Cancer Institute (SCI), Stanford, California, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
- Prev
- 1
- 2
- Next